<Suppliers Price>

G-29701

Names

[ CAS No. ]:
129-20-4

[ Name ]:
G-29701

[Synonym ]:
p-Oxyphenylbutazone
oxyphenbutazon
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione G 27202
Oxazolidin
ossifenbutazone
EINECS 204-936-2
oxyphenylbutazone
MFCD00057278
Idrobutazina
Oxyphenbutazone
Tanderil
Oxiphenbutazone
Oxi-Fenibutol
Oxifenylbutazon
Etrozolidina

Biological Activity

[Description]:

Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis[1][2].

[Related Catalog]:

Research Areas >> Cancer
Research Areas >> Infection
Research Areas >> Inflammation/Immunology
Signaling Pathways >> Immunology/Inflammation >> COX
Signaling Pathways >> Anti-infection >> Bacterial

[Target]

COX[1]


[In Vitro]

Oxyphenbutazone enhances the anticancer efficiency of methotrexate (MTX) in Hep3B cells[1]. Oxyphenbutazone (2.5 -7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells[1]. Oxyphenbutazone exhibits reparative effects in the hepatocytes[1]. Cell Cytotoxicity Assay[1] Cell Line: Hep3B cells Concentration: 2.5 µM, 5 µM, 7.5 µM Incubation Time: 48 hours Result: Enhanced the cytotoxicity of MTX.

[In Vivo]

Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.)[1]. Animal Model: 5–6 weeks Wistar strain albino male rats (150–220 g)[1] Dosage: 70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week) Administration: Oral administration; once a week; in two divided doses; for 13 weeks Result: Exerted potential anticancer activity in rats when co-treatment with MTX.

[References]

[1]. Saleem S, et al. Oxyphenbutazone promotes cytotoxicity in rats and Hep3B cellsvia suppression of PGE2 and deactivation of Wnt/β-catenin signaling pathway. Mol Cell Biochem. 2018 Jul;444(1-2):187-196.

[2]. Gold B, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11.

Chemical & Physical Properties

[ Density]:
1.241g/cm3

[ Boiling Point ]:
485.6ºC at 760mmHg

[ Melting Point ]:
109-111°C

[ Molecular Formula ]:
C19H20N2O3

[ Molecular Weight ]:
324.37400

[ Flash Point ]:
247.5ºC

[ Exact Mass ]:
324.14700

[ PSA ]:
60.85000

[ LogP ]:
3.62340

[ Vapour Pressure ]:
4.7E-10mmHg at 25°C

[ Index of Refraction ]:
1.61

[ Storage condition ]:
Hygroscopic, -20°C Freezer, Under Inert Atmosphere

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UQ8400000
CHEMICAL NAME :
3,5-Pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl-
CAS REGISTRY NUMBER :
129-20-4
BEILSTEIN REFERENCE NO. :
0307474
LAST UPDATED :
199612
DATA ITEMS CITED :
24
MOLECULAR FORMULA :
C19-H20-N2-O3
MOLECULAR WEIGHT :
324.41
WISWESSER LINE NOTATION :
T5VNNV EHJ BR DQ& CR& E4

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
420 mg/kg/4W-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Blood - agranulocytosis Blood - thrombocytopenia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
27 mg/kg/14D
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting Blood - hemorrhage
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
50 mg/kg/7D
TOXIC EFFECTS :
Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
24 mg/kg/4D
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of salivary glands Endocrine - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
329 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
145 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
68 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
330 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
52 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
178 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
104 mg/kg
TOXIC EFFECTS :
Brain and Coverings - recordings from specific areas of CNS Behavioral - excitement Lungs, Thorax, or Respiration - respiratory stimulation
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
1165 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - hamster
DOSE/DURATION :
1180 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
560 mg/kg
SEX/DURATION :
male 28 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
700 mg/kg
SEX/DURATION :
female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
700 mg/kg
SEX/DURATION :
female 10-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth)

MUTATION DATA

TYPE OF TEST :
Sex chromosome loss and nondisjunction
TEST SYSTEM :
Mold - Aspergillus nidulans
DOSE/DURATION :
1 gm/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 26,159,1974 *** REVIEWS *** IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 13,183,1977 IARC Cancer Review:Animal No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 13,183,1977 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5469 No. of Facilities: 25 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 290 (estimated) No. of Female Employees: 121 (estimated)

Safety Information

[ Symbol ]:

GHS07, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H400

[ Precautionary Statements ]:
P273

[ Hazard Codes ]:
Xn,N

[ Risk Phrases ]:
22-50

[ Safety Phrases ]:
61

[ RIDADR ]:
UN 3077 9 / PGIII

[ WGK Germany ]:
3

[ HS Code ]:
2933990090

Synthetic Route

Precursor & DownStream

Customs

[ HS Code ]: 2933990090

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I.

Adverse Drug React. Acute Poisoning Rev. 5(2) , 97-136, (1986)

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part II.

Adverse Drug React. Acute Poisoning Rev. 5(3) , 181-96, (1986)

Disposition and tolerance of suxibuzone in horses.

Equine Vet. J. 31(5) , 411-6, (1999)

Suxibuzone (SBZ), a nonsteroidal anti-inflammatory drug, was administered to 6 horses at a dose rate of 7.5 mg/kg bwt by intravenous (i.v.) route. Plasma and synovial fluid concentrations of suxibuzon...


More Articles


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.